BPO TV

In this episode of our From the helm series, Bell Direct’s Grady Wulff speaks with Dr. Howie McKibbon, CEO of Botanix Pharmaceuticals (ASX:BOT). Based in Philadelphia, Botanix is a dermatology company focused on advancing its lead product, Sofdra, which is FDA-approved for the treatment of primary axillary hyperhidrosis. With the successful commercialisation of Sofdra, the company is positioned in a growing market.

Dr. McKibbon joins us to discuss the latest developments and outlook for Botanix,. In this conversation, he covers:

• (0:42) an overview of Botanix Pharmaceuticals for investors who may not be familiar with the company
• (1:28) the significance of Sofdra’s FDA approval and the global market potential for its treatment
• (2:48) the competitive landscape within the dermatology space
• (3:45) how Botanix manages costs during the later stages of clinical trials and the factors contributing to its financial strength
• (4:30) insights into what the next 12 months hold for Botanix.

Note: This interview was recorded at the ASX Small to Mid-Cap Conference on 25 September 2024.